Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-19

Clinical Trial Update: Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing an education and guidance programme to promote Eliquis (apixaban) adherence in non-valvular atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-valvular Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2019-08-19